A meta-analysis of the four randomized clinical trials, PIONEER AF-PCI [4], RE-DUAL PCI [5], AUGUSTUS [6], and ENTRUST-AF PCI [7], excluding the arm of the PIONEER AF-PCI [4] in which patients were treated with very low-dose rivaroxaban (2.5 mg twice daily), included 10,057 patients and showed that the use of the more potent P2Y12 inhibitors, prasugrel and ticagrelor, was associated with a significantly increased risk of major or clinically relevant bleeding compared to clopidogrel (RR 1.30; 95% CI 1.06–1.59; p = 0.01) [12], regardless of whether they were used in TAT or DAT. This evidence concerns the gene P2RY12 and atrial fibrillation.